Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia

26 March 2024 - Norgine today announced that the CHMP of the EMA has adopted a positive opinion recommending approval of ...

Read more →

EU recommendations for 2024/2025 seasonal flu vaccine composition

26 March 2024 - EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for ...

Read more →

Highlights from the 18-21 March 2024 CHMP meeting

22 March 2024 - The EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its March 2024 meeting. ...

Read more →

Deliberations at the CHMP regarding the marketing authorisation application in the EU for lecanemab have been rescheduled due to procedural reasons at the EMA

22 March 2024 - Eisai announced today that the oral explanation scheduled for 19 March at the CHMP for lecanemab, ...

Read more →

Astellas receives positive CHMP opinion for Xtandi in additional recurrent early prostate cancer treatment setting

22 March 2024 - If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk ...

Read more →

Outlook Therapeutics receives European Union positive CHMP opinion for ONS-5010 as a treatment for wet AMD

22 March 2024 - Positive opinion serves as a basis for final decision for potential authorisation from the European Commission ...

Read more →

Novartis Fabhalta (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria

22 March 2024 - Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior haemoglobin improvement in the ...

Read more →

Awiqli (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities

21 March 2024 - Novo Nordisk today announced that the European Medicines Agency’s CHMP has adopted a positive opinion, recommending ...

Read more →

UCB receives positive CHMP opinion for Bimzelx (bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa

22 March 2024 - Positive CHMP opinion is supported by data from the two Phase 3 studies, BE HEARD I ...

Read more →

Accelerating stakeholder collaboration to enhance the clinical trials environment in the EU

20 March 2024 - The Accelerating Clinical Trials in the EU (ACT EU) initiative has established a multi-stakeholder platform aimed at ...

Read more →

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) becomes first CAR T cell therapy approved in the European Union in earlier lines for triple-class exposed relapsed and refractory multiple myeloma

20 March 2024 - Abecma demonstrated superiority over standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in ...

Read more →

EMA publishes agenda for 18-21 March 2024 CHMP meeting

18 March 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease

13 March 2024 - Prevenar 20 (20 valent pneumococcal conjugate vaccine) offers the broadest serotype coverage of any paediatric pneumococcal ...

Read more →

Johnson & Johnson submits application to the EMA for Darzalex (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

6 March 2024 - Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly ...

Read more →

CymaBay announces EMA accepts for review the marketing authorisation application for seladelpar for the treatment of primary biliary cholangitis

5 March 2024 - MAA validation follows recent applications for seladelpar to the UK MHRA and US FDA. ...

Read more →